| Symbol | ALT |
|---|---|
| Name | ALTIMMUNE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 910 CLOPPER ROAD,SUITE 201S, GAITHERSBURG, Maryland, 20878, United States |
| Telephone | +1 240 654-1450 |
| Fax | — |
| — | |
| Website | https://www.altimmune.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001326190 |
| Description | Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The companys lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Additional info from NASDAQ: |
2026-05-28 15:00
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
Read more
2026-05-13 17:18
New Form S-8 - Altimmune, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001326190-26-000041 <b>Size:</b> 227 KB
Read more
2026-05-13 11:30
Altimmune Announces First Quarter 2026 Financial Results and Business Update
Read more
2026-05-13 11:15
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Read more
2026-05-12 10:46
New Form SCHEDULE 13G - Altimmune, Inc. <b>Filed:</b> 2026-05-12 <b>AccNo:</b> 0000093751-26-000201 <b>Size:</b> 8 KB
Read more
2026-05-06 11:30
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Read more
2026-05-01 20:23
Lawver Teri L 🟢 acquired 48.8K shares (1 derivative) of Altimmune, Inc. (ALT) at $2.82 Transaction Date: May 01, 2026 | Filing ID: 000002
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07009860 | RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutid… | Phase2 | Alcohol Liver Disease | Recruiting | 2025-06-16 | 2027-08-31 | ClinicalTrials.gov |
| NCT06987513 | RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in t… | Phase2 | Alcohol Use Disorder (AUD) | Active_Not_Recruiting | 2025-05-15 | 2026-06-01 | ClinicalTrials.gov |
| NCT05989711 | IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic … | Phase2 | Non-Alcoholic Steatohepatitis (NASH) | Completed | 2023-07-27 | 2025-11-25 | ClinicalTrials.gov |
| NCT05295875 | Efficacy and Safety of ALT-801 in the Treatment of Obesity | Phase2 | Obesity/Overweight | Completed | 2022-03-31 | 2023-09-28 | ClinicalTrials.gov |
| NCT05292911 | Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects… | Phase1 | Non-Alcoholic Fatty Liver Disease | Completed | 2022-03-09 | 2022-10-31 | ClinicalTrials.gov |
| NCT05134662 | ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) | Phase1 | Type 2 Diabetes | Completed | 2022-02-01 | 2023-03-09 | ClinicalTrials.gov |
| NCT05006885 | ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alc… | Phase1 | Non-Alcoholic Fatty Liver Disease | Completed | 2021-09-30 | 2022-08-17 | ClinicalTrials.gov |
| NCT04972396 | Pemvidutide (ALT-801) DDI Study in Healthy Volunteers | Phase1 | NASH - Nonalcoholic Steatohepatitis | Completed | 2021-09-15 | 2022-05-15 | ClinicalTrials.gov |
| NCT04679909 | Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) | Phase1 | Healthy Volunteers | Completed | 2021-02-25 | 2022-12-21 | ClinicalTrials.gov |
| NCT04684914 | HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) | Phase2 | Hepatitis B, Chronic | Terminated | 2020-12-26 | 2024-04-17 | ClinicalTrials.gov |
| NCT04561245 | ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safet… | Phase1 | Obesity | Completed | 2020-11-10 | 2021-10-29 | ClinicalTrials.gov |
| NCT04442230 | NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) | Phase2 | Coronavirus Infection | Terminated | 2020-10-10 | 2021-02-15 | ClinicalTrials.gov |
| NCT04415749 | NasoShield in Healthy Adults to Study Safety and Immunogenicity | Phase1 | Healthy Volunteers | Completed | 2020-06-15 | 2021-03-15 | ClinicalTrials.gov |
| NCT03760549 | Study of the Safety and Immunogenicity of NasoVAX Extension | — | Influenza | Completed | 2019-01-21 | 2019-02-18 | ClinicalTrials.gov |
| NCT03352466 | NasoShield Study of Safety and Immunogenicity | Phase1 | Healthy Volunteers | Completed | 2018-01-18 | 2019-05-13 | ClinicalTrials.gov |
| NCT03232567 | Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX | Phase2 | Influenza | Completed | 2017-09-18 | 2018-06-15 | ClinicalTrials.gov |
| NCT03163342 | Immune Response Following Seasonal Influenza Vaccination | Phase4 | Influenza | Completed | 2017-05-08 | 2018-06-15 | ClinicalTrials.gov |
| NCT02496897 | Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B | Phase1 | Hepatitis B | Completed | 2015-07-01 | 2018-06-05 | ClinicalTrials.gov |
| NCT00755703 | Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Inf… | Phase1 | Influenza A Subtype H5N1 Infection | Completed | 2008-10-01 | 2011-12-01 | ClinicalTrials.gov |
Total clinical trials: 19
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04415749 |
| NasoShield | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04415749 |
| Placebo | Other | Phase PHASE2 | Alcohol Liver Disease | RECRUITING | NCT07009860 |
| Pemvidutide | Other | Phase PHASE2 | Alcohol Liver Disease | RECRUITING | NCT07009860 |
| Licensed seasonal influenza vaccine | Other | Phase PHASE4 | Influenza | COMPLETED | NCT03163342 |
| Placebo | Other | Phase PHASE2 | Coronavirus Infection | TERMINATED | NCT04442230 |
| NasoVAX | Other | Phase PHASE2 | Coronavirus Infection | TERMINATED | NCT04442230 |
| Placebo | Other | Phase PHASE1 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT05292911 |
| ALT-801 | Other | Phase PHASE1 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT05292911 |
| Placebo | Other | Phase PHASE1 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT05006885 |
| ALT-801 | Other | Phase PHASE1 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT05006885 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04679909 |
| AdCOVID | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04679909 |
| Placebo | Other | Phase PHASE2 | Obesity/Overweight | COMPLETED | NCT05295875 |
| ALT-801 | Other | Phase PHASE2 | Obesity/Overweight | COMPLETED | NCT05295875 |
| NasoVAX | Other | Phase PHASE2 | Influenza | COMPLETED | NCT03232567 |
| IC31® Adjuvant | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02496897 |
| Placebo | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02496897 |
| FP-02.2 Vaccine | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02496897 |
| Subjects were administered NasoVAX high dose | Other | Preclinical | Influenza | COMPLETED | NCT03760549 |
| Placebo | Other | Phase PHASE1 | Type 2 Diabetes | COMPLETED | NCT05134662 |
| ALT-801 | Other | Phase PHASE1 | Type 2 Diabetes | COMPLETED | NCT05134662 |
| Ethinylestradiol and Levonorgestrel | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Digoxin | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Warfarin | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Atorvastatin | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Metformin | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Pemvidutide | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04561245 |
| ALT-801 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT04561245 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03352466 |
| BioThrax | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03352466 |
| NasoShield | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03352466 |
| Placebo | Other | Phase PHASE2 | Alcohol Use Disorder (AUD) | ACTIVE_NOT_RECRUITING | NCT06987513 |
| Pemvidutide | Other | Phase PHASE2 | Alcohol Use Disorder (AUD) | ACTIVE_NOT_RECRUITING | NCT06987513 |
| Placebo | Other | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT04684914 |
| HepTcell | Other | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT04684914 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Pemvidutide | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis (NASH) | COMPLETED | NCT05989711 |
| Ethinylestradiol and Levonorgestrel | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Digoxin | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Warfarin | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Atorvastatin | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Metformin | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT04972396 |
| Pemvidutide | DRUG | Phase PHASE2 | Alcohol Liver Disease | RECRUITING | NCT07009860 |
| HepTcell | BIOLOGICAL | Phase PHASE2 | Hepatitis B, Chronic | TERMINATED | NCT04684914 |
| AdCOVID | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04679909 |
| ALT-801 | DRUG | Phase PHASE2 | Obesity/Overweight | COMPLETED | NCT05295875 |
| Subjects were administered NasoVAX high dose | DRUG | Preclinical | Influenza | COMPLETED | NCT03760549 |
| BioThrax | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03352466 |
| NasoShield | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT04415749 |
| NasoVAX | BIOLOGICAL | Phase PHASE2 | Coronavirus Infection | TERMINATED | NCT04442230 |
| Licensed seasonal influenza vaccine | BIOLOGICAL | Phase PHASE4 | Influenza | COMPLETED | NCT03163342 |
| IC31® Adjuvant | OTHER | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02496897 |
| FP-02.2 Vaccine | BIOLOGICAL | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02496897 |
| Placebo | OTHER | Phase PHASE2 | Alcohol Liver Disease | RECRUITING | NCT07009860 |
| Pandemic Influenza Vaccine | BIOLOGICAL | Phase PHASE1 | Influenza A Subtype H5N1 Infection | COMPLETED | NCT00755703 |
Total products: 85